Who are Capecitabine Oral Product's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Xeloda, Fudr, Folic Acid, Folferi and celecoxib, Irinotecan, 5FU, leucovorin, Unitrim.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/capecitabine-oral-product.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Capecitabine Oral Product — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Capecitabine Oral Product (Capecitabine Oral Product) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimetabolite; Fluoropyrimidine. Area: Oncology.

phase 3 Antimetabolite; Fluoropyrimidine Thymidylate synthase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Capecitabine Oral Product (Capecitabine Oral Product) — Abramson Cancer Center at Penn Medicine. Capecitabine is a prodrug that is converted to fluorouracil in the body, which inhibits thymidylate synthase and disrupts DNA synthesis to kill rapidly dividing cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Capecitabine Oral Product TARGET	Capecitabine Oral Product	Abramson Cancer Center at Penn Medicine	phase 3	Antimetabolite; Fluoropyrimidine	Thymidylate synthase
Xeloda	capecitabine	Cheplapharm	marketed	Nucleoside Metabolic Inhibitor [EPC]	Thymidylate synthase	1998-01-01
Fudr	FLOXURIDINE		marketed	Antimetabolite [EPC]	Thymidylate synthase	1970-01-01
Folic Acid	FOLIC ACID	Pfizer	marketed	Vitamin C [EPC]	Thymidylate synthase	1946-01-01
Folferi and celecoxib	Folferi and celecoxib	Sherief Abd-Elsalam	marketed	Chemotherapy combination with COX-2 inhibitor	Topoisomerase I (irinotecan), thymidylate synthase (fluorouracil), COX-2
Irinotecan, 5FU, leucovorin	Irinotecan, 5FU, leucovorin	Asan Medical Center	marketed	Chemotherapy combination (topoisomerase I inhibitor + antimetabolite)	Topoisomerase I; thymidylate synthase
Unitrim	BRODIMOPRIM		marketed	brodimoprim	Bifunctional dihydrofolate reductase-thymidylate synthase, Dihydrofolate reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimetabolite; Fluoropyrimidine class)

Abramson Cancer Center at Penn Medicine · 1 drug in this class
Qilu Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Capecitabine Oral Product — Competitive Intelligence Brief. https://druglandscape.com/ci/capecitabine-oral-product. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab